Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies Journal Article
| Authors: | Balagula, Y.; Lacouture, M. E.; Cotliar, J. A. |
| Article Title: | Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies |
| Abstract: | The discovery of the intricate intracellular signaling networks that regulate normal cellular proliferation and survival but can also drive the oncogenic process when aberrantly activated has led to the emergence of targeted agents in oncology. The introduction of such agents has resulted in improved survival and more tolerable treatments, reducing systemic toxicities such as myelosuppression. Nevertheless, it has become evident that these agents are associated with a wide spectrum of dermatologic toxicities that often manifest in cosmetically sensitive areas and may affect the majority of patients. Associated pain and pruritus can negatively impact quality of life, resulting in dose modification or treatment interruptions that interfere with potentially life-prolonging therapy. Extensive efforts throughout the past decade have concentrated on describing the clinicohistopathologic characteristics, elucidating the underlying mechanisms, and investigating potential management strategies. Currently, however, proposed treatment guidelines arise from expert opinions, anecdotal evidence, and few data from clinical trials. This article reviews the spectrum of dermatologic toxicities associated with a variety of targeted agents used alone or in combination with other modalities, delineating their clinical presentation, underlying mechanisms, and management options. © 2010 Elsevier Inc. |
| Keywords: | signal transduction; cancer chemotherapy; antibiotic agent; prednisone; clinical feature; clinical trial; review; squamous cell carcinoma; sorafenib; erlotinib; placebo; sunitinib; drug dose reduction; drug safety; drug withdrawal; nonhuman; risk benefit analysis; skin toxicity; solid tumor; drug targeting; pathophysiology; cancer radiotherapy; antineoplastic agent; colorectal cancer; imatinib; unindexed drug; quality of life; drug eruption; breast cancer; actinic keratosis; lung non small cell cancer; mucosa inflammation; stomatitis; patient education; steroid; antineoplastic activity; dasatinib; cetuximab; kidney carcinoma; deforolimus; panitumumab; nail disease; pruritus; rash; drug mechanism; colon cancer; acne; gefitinib; hyperpigmentation; hair disease; skin discoloration; telangiectasia; hydrocortisone; lidocaine; doxycycline; hand foot syndrome; tetracycline; minocycline; alopecia; photosensitivity; lapatinib; radiation dermatitis; head and neck carcinoma; epidermal growth factor receptor kinase inhibitor; dysuria; paronychia; xerosis; keratoacanthoma; pimecrolimus; clobetasol; hypopigmentation; hypertrichosis; ammonium lactate; clindamycin; fluocinonide; silver nitrate; tazarotene; urea; aphthous ulcer; depigmentation; dysesthesia; genital system disease; mouth ulcer; mucosal dryness; nail discoloration; nose ulcer; onycholysis; papulopustular rash; pigment disorder; seborrheic dermatitis like rash; subungual hemorrhage; subungual splinter hemorrhage; trichomegaly |
| Journal Title: | The Journal of Supportive Oncology |
| Volume: | 8 |
| Issue: | 4 |
| ISSN: | 1544-6794 |
| Publisher: | BioLink Communications |
| Date Published: | 2010-07-01 |
| Start Page: | 149 |
| End Page: | 161 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 20822032 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: JSOOB" - "Source: Scopus" |
